Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Toxicological highlights

Robert E Chapin1

  • 1Developmental and Reproductive Toxicology Center of Expertise, Pfizer Global R&D, Eastern Point Rd, Groton, CT 06340, USA. robert.e.chapin@pfizer.com

Toxicological Sciences : an Official Journal of the Society of Toxicology
|August 19, 2007
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictivity of Nonclinical Male Reproductive Findings for Human Effects.

Birth defects research·2017
Same author

Use of Rat Primary Mesenteric Cells for the Prediction of PDE4 Inhibitor Drug-Induced Vascular Injury.

Toxicological sciences : an official journal of the Society of Toxicology·2017
Same author

Alternative Models of Developmental and Reproductive Toxicity in Pharmaceutical Risk Assessment and the 3Rs.

ILAR journal·2017
Same author

Lost in translation: The search for an in vitro screen for spermatogenic toxicity.

Birth defects research. Part B, Developmental and reproductive toxicology·2016
Same author

Effects of the Janus Kinase Inhibitor, Tofacitinib, on Testicular Leydig Cell Hyperplasia and Adenoma in Rats, and on Prolactin Signaling in Cultured Primary Rat Leydig Cells.

Toxicological sciences : an official journal of the Society of Toxicology·2016
Same author

Goldilocks' Determination of What New In Vivo Data are "Just Right" for Different Common Drug Development Scenarios, Part 1.

Birth defects research. Part B, Developmental and reproductive toxicology·2016